Pure Global AI
NCT06308939Not yet recruiting

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Explore the Efficacy and Safety of Eribulin Combined With Sintilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer
Zhejiang Cancer HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Metastatic Breast Cancer
Drug/Device/Intervention
Eribulin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Zhejiang Cancer Hospital
Location
Hangzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Mar 08, 2024
End date
Aug 31, 2026
Enrollment
81 participants
Primary outcome

Objective Response Rate (ORR)

Summary

This is a multicenter, single-arm,Phase II clinical trial to explore the efficacy and safety
 of Eribulin combined with Sintilimab in the first-line treatment of unresectable locally
 advanced or metastatic HER2-negative breast cancer.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastMalignant neoplasm: Overlapping lesion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06308939
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06308939 through Pure Global AI's free database. This Phase 2 trial is sponsored by Zhejiang Cancer Hospital and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 81 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.